[SAT-377] Vitamin D Deficiency (VDD) and Major Depressive Disorder (MDD): A Causal or Casual Association?

Sonal Pathak, Mohammad Asim Nisar, David S Rosenthal. Bayhealth Endocrinology, Dover, DE; St Lukes Roosevelt Hospital, New York, NY; Nassau University Medical Center, East Meadow, NY.

Background: Vit D is associated with several metabolic, musculoskeletal and immunologic effects. Its psychosomatic effects have been speculated, but less studied. We present 3 cases of VDD in patients with MDD, with significant improvement in mood after repletion. We'll discuss controversies regarding effects of Vit D on mood and cognitive disorders and a potential role of Vit D replacement as an adjunct in management of MDD in Vit D deficient patients.
Cases: Patient #1 was a 42 y/o F treated for hypothyroidism with obesity and depression for 5 years. She was euthyroid on a stable dose of L-T4 with TSH 1.24µIU/ml (0.45-4.50). In spite of optimization of antidepressant therapy, her depression had exacerbated over the preceding 6 months (*BDI 32). Patients #2 and #3 were females aged 58 and 66 years, being treated for DM2 and also suffered from depression (*BDI 26 and 21 respectively). VDD was suspected based on risk factors/symptoms. Presenting 25(OH)VitD levels were low (normal 30-85 ng/ml) at 12, 8.9 and 14.5ng/ml respectively. After Vit D repletion, 25(OH)Vit D levels became sufficient at 32, 34.6, and 38ng/ml respectively. Other medications and environmental factors were unchanged. Depressive symptoms were reported to be significantly improved by all patients (*BDI 12, 8 and 16 respectively).
Discussion: Vit D receptors and α-hydroxylases have been mapped throughout the brain, including the amygdala/limbic system, where behavior/emotions are regulated. Vit D is also involved in release of neurotransmitters like serotonin/dopamine in brain. Association of VDD with dementia & schizophrenia has been well studied. However, data from epidemiological studies and a few randomized controlled trials on relationship between Vit D status and depression has been equivocal, although suggestive of a possible causal association. Effects of Vit D replacement in deficient patients with MDD has been less studied, with a few reports suggesting a significant positive effect, but limited by confounding variables.
Conclusion: Detection and treatment of VDD in patients with depression may be an easy and cost-effective adjunct to mainstream therapies; however, more research is needed to definitively confirm these findings.
*Beck Depression Inventory score (BDI): 0–9 minimal depression; 10–18 mild depression; 19–29 moderate depression; 30–63 severe depression.

1. Milaneschi et al, JCEM 95(7), July 2010. 2. Ganji et al, Int Archives of Medicine, 2010, 3:29. 3. Bertone-Johnson, Nutr Rev. August 2009; 67(8).

Nothing to Disclose: SP, MAN, DSR

Date: Saturday, June 23, 2012
Session Info: POSTER SESSION: Metabolic Bone Diseases (1:30 PM-3:30 PM)
Presentation Time: 1:30 pm
Room: Expo

Embargo Policy
Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.

Disclaimer Statement
The information presented at ENDO news conferences and within the Research Summaries Book represents the opinion of the presenters and authors and is not necessarily the view of The Endocrine Society. The Endocrine Society makes no representation as to the truth or warranty, accuracy, or originality of the information presented.

For additional information, please contact The Endocrine Society’s Public Affairs Department at 240-482-1380 or alohr@endo-society.org.


Close Window